Team members involved:

Team members involved:

At the time of our investment, Medscreen was Europe’s leading provider of drug and alcohol testing services, incorporating global sample collection, laboratory analysis, on-call services, programme management and the provision of education and training.

  • Investment: March 2002
  • Sector: Business services
  • Business: Drug and alcohol testing
  • Growth Strategy: Product development and international expansion

Why we invested

New regulation, and a growing emphasis on workplace health management, were driving increased adoption of drug and alcohol testing across a number of industries. Medscreen was the leading UK provider, with a long-standing client base in the maritime, oil and gas, transport and other sectors – and was one of the few companies able to service international demand due to its unique international collection network and secure chain of custody. This was an opportunity to back a leading company in executing a compelling growth strategy, both organically and by acquisition.

The result

During the nearly six years of our ownership, Medscreen delivered strong growth in sales and profits. This was aided by the acquisition of Drug Testing International, Medscreen’s largest US competitor, creating the leading international player in its market. A considerable investment was also made in increasing Medscreen’s laboratory capacity, and in expanding into the occupational health market.  In 2006, Medscreen was successfully sold to a strategic buyer.

Read more about our Business & Financial Services strategy

Bowmark’s support and assistance was indispensable, and they added real value to our business.

Fiona Begley, Managing Director
Back to portfolio